ABIVAX Abstract On Obefazimod Phase 2B Results Selected For

Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance

Related Keywords

Austria , Leuven , Region Flamande , Belgium , United States , Vienna , Wien , Paris , France General , France , Regina Jehle , Enregistrement Universel , Ghislaine Gasparetto , Jeanene Timberlake , Ligia Vela Reid , Anne Hennecke , Severine Vermeire , Gastroenterol Hepatol , Mc Services , University Hospitals Leuven , Rooney Partners , Relations Investors Europe , Euronext , Euronext Paris , United European Gastroenterology , Science Lounge , Virtual Poster , Inflammatory Bowel Diseases , Poster Session , Lancet Gastroenterology , Mayo Score , Review Board , Truffle Capital , French Autorit , Des March , Impact Factor , Citation Reports , Lancet Gastroenterol Hepatol , Abivax , Abstract , Obefazimod , Hase , Results , Elected , Moderated , Poster , Presentation , Eek , 022 ,